Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Clinical trial NCT05311579 · UNKNOWN

Trial details

NCT number: NCT05311579
Sponsor: Lei Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Carcinoma Survival Outcomes Adverse Events Niraparib Anlotinib CA125 Chemotherapy Targeted Therapy Recurrent Ovarian Cancer

Start date: 2022-03-27
Primary completion: 2023-03-27
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.